Idalopirdine

Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of October 2013 it is in phase III clinical trials.[2]

Idalopirdine
Clinical data
Other namesLu-AE-58054
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.245.270
Chemical and physical data
FormulaC20H19F5N2O
Molar mass398.37 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose.[3] Two further phase III trials failed too, the company confirmed in early 2017.[3]

See also

References
  1. "U.S. Development Programs. - Lundbeck".
  2. "Search of: Lu AE58054 - List Results - ClinicalTrials.gov".
  3. PhIII Alzheimer’s flop takes chunk out of Lundbeck, hits Axovant with aftershocks Sept 2016


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.